Literature DB >> 33958712

Genomic landscape of hepatocarcinogenesis.

Tatsuhiro Shibata1.   

Abstract

Hepatocellular carcinoma (HCC) is a global health issue and the fourth leading cause of cancer deaths worldwide. Large-scale HCC genome sequencing analyses have identified core drivers (TERT, TP53, and CTNNB1/AXIN1) as initial molecular events, and other low-frequent drivers that include therapeutically targetable ones. The recent genetic analysis uncovered a distinctive driver gene landscape in precancerous lesions, arguing a discontinuous process at early HCC development. In advanced tumors, intra-tumoral heterogeneity through clonal evolution processes is common, and it displays clear geographic segregation genetically and epigenetically. Diverse epidemiological risk factors for HCC mirrors heterogeneous mutational processes among patient cohorts with distinctive ethnicity, environmental exposures, and lifestyles. The genetic information of individual tumors has been utilized for optimizing treatments, early diagnosis, and monitoring recurrence. It will expand the opportunity for screening high-risk populations, thereby preventing hepatocarcinogenesis in the near future.
© 2021. The Author(s), under exclusive licence to The Japan Society of Human Genetics.

Entities:  

Mesh:

Year:  2021        PMID: 33958712     DOI: 10.1038/s10038-021-00928-8

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  5 in total

1.  ZIC5 promotes human hepatocellular carcinoma cell proliferation through upregulating COL1A1.

Authors:  Wenping Song; Weijiang Yu; Ding Li; Cheng Cheng; Xuan Wu; Jinhua Chen; Wenzhou Zhang
Journal:  J Gastrointest Oncol       Date:  2022-06

2.  Detection of CTNNB1 Hotspot Mutations in Cell-Free DNA from the Urine of Hepatocellular Carcinoma Patients.

Authors:  Selena Y Lin; Ting-Tsung Chang; Jamin D Steffen; Sitong Chen; Surbhi Jain; Wei Song; Yih-Jyh Lin; Ying-Hsiu Su
Journal:  Diagnostics (Basel)       Date:  2021-08-14

3.  Diagnostic, Therapeutic, and Prognostic Value of the m6A Writer Complex in Hepatocellular Carcinoma.

Authors:  Zongting Gu; Yongxing Du; Xueping Zhao; Chengfeng Wang
Journal:  Front Cell Dev Biol       Date:  2022-02-09

4.  Prognostic Value of MUC16 Mutation and Its Correlation with Immunity in Hepatocellular Carcinoma Patients.

Authors:  Bing Liu; Zhicheng Dong; Yingzhi Lu; Jianhua Ma; Zhaoming Ma; Hongwei Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-18       Impact factor: 2.650

Review 5.  Advances in postoperative adjuvant therapy for primary liver cancer.

Authors:  Zhi-Ming Zeng; Ning Mo; Jie Zeng; Fu-Chao Ma; Yan-Feng Jiang; Hua-Sheng Huang; Xi-Wen Liao; Guang-Zhi Zhu; Jie Ma; Tao Peng
Journal:  World J Gastrointest Oncol       Date:  2022-09-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.